IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: I. Luttichuys who wrote (1031)	6/24/1997 9:57:00 AM
From: Roader	of 1762

Well it was nice knowing you all. IDEC's potential glory days have come to an end. Roader Dow Jones News Service via Dow Jones PHILADELPHIA (Dow Jones)--Idec Pharmaceuticals Corp. (IDPH) and SmithKline Beecham PLC (SBH) suspended phase III trials of IDEC-CE9.1/SB-210396 for the treatment of rheumatoid arthritis. In a joint press release Tuesday, the companies said the decision was based on observations that a higher amount of patients had reduced CD4 cell counts in phase III trials compared with phase II trials. Even though there were no reports of side effects related to lower CD4 counts in this trial, the companies placed a hold on the current clinical trials pending a thorough review and analysis of the data. A blinded assessment of CD4 cell counts in the current phase III trial showed that 35 out of 103 patients completing the first month of treatment had reduced CD4 cell counts, compared with 10 of 136 measured at the same point in the phase II trial. Five out of 10 patients in phase II had a reduction of CD4 counts for three months or greater. As part of an ongoing follow-up, the companies said they will assess the duration of CD4 count reduction in the phase III trial. The companies made no efficacy assessment to date, but said an evaluation will be made for patients who have completed the initial part of the phase III trial. The phase II study demonstrated ''significant clinical improvement'' in the signs and symptoms of rheumatoid arthritis with IDEC-CE9.1/SB-210396 treatment, the companies said. (MORE) DOW JONES NEWS 06-24-97 9:53 AM -- 9 53 AM EDT 06-24-97 :TICKER: IDPH SBH SB.L :SUBJECT: BIOT DRUG CA ENGL Copyright (c) 1997 Dow Jones and Company, Inc. Received by NewsEDGE/LAN: 6/24/97 9:52 AM

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next